

APC anti-human IFN- γ Antibody

Catalog# / Size	506510 / 100 tests
Clone	B27
Regulatory Status	RUO
Other Names	Interferon- γ , Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF), IFN-g, IFN-gamma
Isotype	Mouse IgG1, κ
Description	Interferon- γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN- γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN- γ can upregulate MHC class I and II antigen expression by antigen-presenting cells. The B27 antibody reacts with the human interferon- γ . The B27 antibody can neutralize the bioactivity of natural or recombinant IFN- γ .

Product Details

Verified Reactivity	Human
Reported Reactivity	Chimpanzee, Baboon, Cynomolgus, Rhesus, African Green, Pigtailed Macaque, Sooty Mangabey
Antibody Type	Monoclonal
Host Species	Mouse
Immunogen	<i>E. coli</i> -expressed recombinant human IFN- γ
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation	The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	ICFC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is 5 μ l per million cells in 100 μ l staining volume or 5 μ l per 100 μ l of whole blood.
Excitation Laser	Red Laser (633 nm)
Application Notes	Flow Cytometry²: The fluorochrome-labeled B27 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN- γ -producing cells within mixed cell populations. For intracellular cytokine staining protocol, please visit www.biolegend.com and click on the support section. Neutralization^{1,3,6,7}: The Ultra-LEAF™ Purified antibody (Endotoxin <0.01 EU/ μ g, Azide-Free, 0.2 μ m filtered) is recommended for neutralization of human IFN- γ bioactivity (Cat. No. 506531).

Application References

1. Favre C, *et al.* 1989. *Molec. Immunol.* 26:17. (Neut)
2. Kaur A, *et al.* 2002. *J Virol.* 76:3646.
3. Abrams J, *et al.* 1992. *Immunol. Rev.* 127:5. (Neut)
4. Andersson U, *et al.* 1999. *Detection and quantification of gene expression*. New York:Springer-Verlag.
5. Rout N, *et al.* 2010. *PLoS One* 5:e9787. (FC)
6. Acosta-Rodriguez EV, *et al.* 2007. *Nat. Immunol.* 9:942-9. (Neut)
7. Gangur V, *et al.* 1998. *FASEB J.* 12:705-13. (Neut)

Product Citations

1. Nesterenko PA, *et al.* 2021. *Cell Rep.* 37:110167. [PubMed](#)
2. Laurent A, *et al.* 2014. *PLoS One.* 9:103683. [PubMed](#)

3. Seo YB, *et al.* 2021. *Vaccines* (Basel). 9: . [PubMed](#)
4. Marques RM, *et al.* 2021. *Cell Death Differ.* 28:3140. [PubMed](#)
5. Cheng L, *et al.* 2021. *Cancer Immunol Immunother.* Online ahead of print. [PubMed](#)
6. Costa-Martins AG, *et al.* 2021. *Cell Rep Med.* 2:100465. [PubMed](#)
7. Shi Z, *et al.* 2021. *Ann Clin Transl Neurol.* 8:43. [PubMed](#)
8. Kan S, *et al.* 2020. *Int J Oncol.* 57:1047. [PubMed](#)
9. Blandine Monel *et al.* 2019. *Cell reports.* 27(1):142-153 . [PubMed](#)
10. Torres-Ruiz J, *et al.* 2021. *Front Immunol.* 12:689966. [PubMed](#)
11. Juno JA, *et al.* 2020. *Nat Med.* 26:1428. [PubMed](#)
12. Rölle A, *et al.* 2018. *Cell Rep.* 24:1967. [PubMed](#)
13. Alrubayyi A, *et al.* 2021. *Nat Commun.* 12:5839. [PubMed](#)
14. Srivastava S, *et al.* 2019. *Cancer Cell.* 35:489. [PubMed](#)
15. Godbersen C, *et al.* 2017. *Mol Cancer Ther.* 16:1335. [PubMed](#)
16. Zhuang X, *et al.* 2019. *Cancer Immunol Res.* 0.94375. [PubMed](#)
17. Johnson JK, *et al.* 2022. *Methods Mol Biol.* 2470:641. [PubMed](#)
18. Wei Z, *et al.* 2021. *Nat Commun.* 0.805555556. [PubMed](#)
19. Matsuzawa T, *et al.* 2017. *J Dermatol Sci.* 10.1016/j.jdermsci.2017.03.015. [PubMed](#)
20. Salvany-Celades M *et al.* 2019. *Cell Rep.* 27(9):2537-2547 . [PubMed](#)
21. Qiu X, *et al.* 2013. *Sci Transl Med.* 16:207. [PubMed](#)
22. Robert R, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0184278. [PubMed](#)
23. Min HK, *et al.* 2021. *Immune Netw.* 21:e43. [PubMed](#)
24. Marzan-Rivera N, *et al.* 2022. *iScience.* 25:104764. [PubMed](#)
25. Lee IK, *et al.* 2020. *Cancers* (Basel). 12: . [PubMed](#)
26. Nesterenko PA, *et al.* 2021. *Proc Natl Acad Sci U S A.* 118: . [PubMed](#)

RRID AB_315443 (BioLegend Cat. No. 506510)

Antigen Details

Structure	Cytokine; dimer; 20-25 kD (Mammalian)
Bioactivity	Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC
Cell Sources	CD8 ⁺ and CD4 ⁺ T cells, NK cells
Cell Targets	T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors	IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type	Tregs
Biology Area	Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family	Cytokines/Chemokines
Antigen References	<ol style="list-style-type: none"> 1. Fitzgerald K, <i>et al.</i> Eds. 2001. <i>The Cytokine FactsBook</i>. Academic Press San Diego. 2. De Maeyer E, <i>et al.</i> 1992. <i>Curr. Opin. Immunol.</i> 4:321. 3. Farrar M, <i>et al.</i> 1993. <i>Annu. Rev. Immunol.</i> 11:571. 4. Gray P, <i>et al.</i> 1987. <i>Lymphokines</i> 13:151.
Regulation	Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2
Gene ID	3458

Related Protocols


[Surface and Intracellular Cytokine Staining for Flow Cytometry - Video](#)

[Intracellular Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-human IFN-γ, FITC anti-human IFN-γ, PE anti-human IFN-γ, Purified anti-human IFN-γ, Alexa Fluor® 700 anti-human IFN-γ, PE/Cyanine7 anti-human IFN-γ, Purified anti-human IFN-γ (Maxpar® Ready), APC/Cyanine7 anti-human IFN-γ, Pacific Blue™ anti-human IFN-γ, PerCP/Cyanine5.5 anti-human IFN-γ, PE/Dazzle™ 594 anti-human IFN-γ, Ultra-LEAF™ Purified anti-human IFN-γ, Brilliant Violet 605™ anti-human IFN-γ, Brilliant Violet 510™ anti-human IFN-γ, Brilliant Violet 421™ anti-human IFN-γ

Product Data



PMA+ionomycin-stimulated (6 hours)
human peripheral blood lymphocytes
intracellularly stained with B27 APC and
CD3 (FIT3a) PE/Cy5

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587